Final Program

WEDNESDAY • MAY 18 391
L21
AIRWAYS CLINICAL RESEARCH CENTERS , ALA
LATE BREAKING RESULTS FOR THE ALA-ACRC
LASST STUDY
12:15 p.m. - 1:15 p.m. MOSCONE CENTER
Room 3006/3008 (West Building, Level 3)
Target Audience
Physicians, clinical scientists, nurses, paraprofessionals, educators, health
care providers.
Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings about new, safe, and effective approaches to asthma
treatment;
• gain new strategies to manage the care of asthma;
• learn new findings about adherence, safety, and tolerability of LASST.
The ALA Airways Clinical Research Centers’ (ACRC) purpose is to conduct clinical
trials with practical importance to both adults and children with COPD and asthma.
One of the trials was the LASST Study (Long-acting Beta Agonist Step Down
Study). This trial verified these findings: to test the hypothesis that in patients with
well-controlled asthma on combination ICS/LABA, discontinuing LABA while
continuing with the same ICS dose will be inferior to continuing LABA and reducing
the dose of ICS in preventing treatment failure during step-down therapy. This
session will be the first presentation of the results of the LASST Study.
Chairing: W.C. Bailey, MD, Birmingham, AL
R.A. Wise, MD, Baltimore, MD
12:15 LASST Background and Rationale
K. Blake, PharmD, Jacksonville, FL
12:30 LASST Study Design and Baseline Characteristics
C. Bime, MD, Tucson, AZ
12:45 LASST Main Results, Summary, and Conclusions
L. Rogers, MD, New York, NY
1:00 Discussion/Questions and Answers
R.A. Wise, MD, Baltimore, MD
L22
NATIONAL INSTITUTE FOR
OCCUPATIONAL SAFETY AND HEALTH
RESPIRATORY HAZARDS OF WORKING WITH
METALS: FROM MACROPHAGES TO
MICROBIOMES
12:15 p.m. - 1:15 p.m. MOSCONE CENTER
Room 3020/3022 (West Building, Level 3)
Target Audience
Providers of lung health; clinicians caring for industrial workers; clinicians and
researchers with interest in exposure-related lung disease.
Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings about exposure to metals (beryllium, indium) and
disease;
• recognize occupational causes of lung disease related to exposure to
metals or metalworking fluid;
• improve understanding of the potential role of the lung microbiome in
occupational lung disease.
This session will highlight recent research at NIOSH on unique lung diseases
related to work with metals. Both well-described and novel diseases will be
discussed. Findings related to clinical features and exposure-response
relationships will be presented. Implications for disease prevention will be
explored.
Chairing: K. Cummings, MD, MPH, Morgantown, WV
12:15 NIOSH Research on Beryllium Disease
E. Fechter-Leggett, DVM, Morgantown, WV
12:30 Understanding Indium Lung Disease
R. Harvey, DVM, Morgantown, WV
12:45 A Novel Lung Disease Related to Metalworking Fluid
R. Nett, MD, Morgantown, WV
1:00 Lung and Workplace Microbiomes in a Metalworking Fluid
Environment
L. Segal, MD, New York, NY
L23
U.S. FOOD AND DRUG ADMINISTRATION
PULMONARY UPDATE FROM THE U.S. FOOD AND
DRUG ADMINISTRATION
12:15 p.m. - 1:15 p.m. MOSCONE CENTER
Room 3016/3018 (West Building, Level 3)
Target Audience
Clinicians in practice, researchers, pharmaceutical industry representatives,
international regulators.
Objectives
At the conclusion of this session, the participant will be able to:
• understand how FDA-approved biomarkers can be used to enhance clinical
trial drug development;
• learn new therapeutic targets for asthma (general asthma population as
well as specific phenotypic subsets);
• integrate new treatment options regarding maintenance bronchodilator
choices for management of stable asthma, and understand the role of
clinical and biomarker criteria for patient selection for anti-IL-5 therapy.
The most recent regulatory FDA actions including discussion of current safety
and efficacy issues of products for pulmonary indications will be presented. A
summary of the Agency’s biomarker qualification process exemplified by the
recent qualification of fibrinogen for use in COPD clinical trials will be discussed.
Recent approvals for asthma highlighting targeted therapy to specific asthma
phenotypes, as well as the use of a long-acting anticholinergic as a new
bronchodilator in asthma will be presented.
Chairing: L.I. Gilbert-McClain, MD, Silver Spring, MD
WEDNESDAY MID-DAY
ATS 2016 • San Francisco